Gainesville, FL, United States of America

William W Hauswirth

This inventor holds 26 USPTO granted patents and 19 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Gene Therapy. Top assignees: University of Florida Research Foundation Inc., University of Pennsylvania, University of Washington. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: William W Hauswirth. Retrieved from https://idiyas.com/inventor/william-w-hauswirth

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 19)

% Patents Active = 84.6

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 3.8

ph-index = 10

Forward Citations = 626(Granted Patents)

Company Filing History:

26 out of 3,058

University of Florida Research Foundation Inc.

patents

6 out of 2,663

University of Pennsylvania

patents

3 out of 2,173

University of Washington

The Medical College of Wisconsin, Inc.

patents

6. 1 out of 16,048

University of California

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Gene Therapy

AAV Vectors

Retinal Degeneration

Cone Photoreceptor

Otoferlin

Dominant Retinitis Pigmentosa

Angiotensin Peptides

Ribozyme Compositions

Pseudotyped Recombinant AAV

Chimeric Promoters

Vascular Endothelial Cells

Leber's Congenital Amaurosis

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12390146 - Reagents and methods for modulating cone photoreceptor activity (2025-08-19),

2. 12359221 - Compositions and methods for expressing otoferlin (2025-07-15),

3. 12203074 - Compositions and methods for treatment of dominant retinitis pigmentosa (2025-01-21),

4. 12188041 - Codon optimized otoferlin AAV dual vector gene therapy (2025-01-07),

5. 11512326 - Small angiotensin peptide expression system in mammalian cells (2022-11-29),

6. 11325956 - Dual-AAV vector-based systems and methods for delivering oversized genes to mammalian cells (2022-05-10),

7. 11160488 - Reagents and methods for modulating cone photoreceptor activity (2021-11-02),

8. 11118185 - AAV vectors for treatment of dominant retinitis pigmentosa (2021-09-14),

9. 10648000 - rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes (2020-05-12),

10. 10533187 - Methods and compositions for restoration of cone function in BCM (2020-01-14),

11. 10426844 - Capsid-mutated rAAV vectors and methods of use (2019-10-01),

12. 10383922 - AAV-mediated gene therapy for RPGR X-linked retinal degeneration (2019-08-20),

13. 10214572 - Dual-AAV vector-based systems and methods for delivering oversized genes to mammalian cells (2019-02-26),

14. 9816108 - rAAV-guanylate cyclase compositions and methods for treating lebers congenital amaurosis-1 (LCA1) (2017-11-14),

15. 9770491 - AAV-mediated gene therapy for RPGR X-linked retinal degeneration (2017-09-26),

Title: The Innovations of William W. Hauswirth in Retinal Gene Therapy

Introduction

William W. Hauswirth, based in Gainesville, Florida, is an accomplished inventor and researcher renowned for his significant contributions to the field of retinal gene therapy. With an impressive portfolio of 24 patents, Hauswirth has dedicated his career to developing innovative treatments for genetic disorders affecting vision, particularly retinitis pigmentosa.

Latest Patents

Among Hauswirth's latest innovations are two noteworthy patents. The first patent focuses on "Compositions and methods for treatment of dominant retinitis pigmentosa." This groundbreaking work involves methods and compositions that aim to reduce the expression of mutant alleles of the RHO gene associated with retinitis pigmentosa through the delivery of interfering RNA. Additionally, the patent outlines the delivery of a replacement RHO coding sequence resistant to the interfering RNA.

The second patent, titled "Codon optimized otoferlin AAV dual vector gene therapy," details methods and compositions for effective expression of the Otoferlin protein using adeno-associated viral (AAV) particles. This patent has crucial implications for treating Autosomal Recessive Deafness 9 (DFNB9) and includes kits comprising these innovative compositions.

Career Highlights

William W. Hauswirth has been associated with prestigious research institutions, including the University of Florida Research Foundation and the University of Pennsylvania. His work has significantly advanced the understanding and potential treatments for hereditary retinal diseases, showcasing his commitment to improving patient outcomes through innovative research.

Collaborations

Throughout his career, Hauswirth has collaborated with esteemed colleagues such as Sanford Leon Boye and Alfred Samuel Lewin. These partnerships have enriched his research endeavors and contributed to the development of transformative therapies in the field of genetics and vision restoration.

Conclusion

In conclusion, William W. Hauswirth stands as a pioneering inventor in the realm of retinal gene therapy, with a robust portfolio of patents that reflect his dedication to addressing genetic disorders. His innovative approaches continue to pave the way for novel treatments, offering hope to individuals affected by conditions like retinitis pigmentosa and DFNB9. Hauswirth’s contributions underscore the critical role of inventors in advancing medical science and improving quality of life for patients worldwide.

Profile summary based on public USPTO records.